CRL · XBRL financial data

Charles River Laboratories International financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRL's year ends in late December)

In millions of dollars	FY 2020Dec 26, 2020	FY 2021Dec 25, 2021	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Dec 27, 2025
Revenue from contracts with customers	2,924	3,540	3,976	4,129	4,050	4,015
Selling, general and administrative	529	620	665	748	751	743
Operating income (loss)	433	590	651	617	227	25
Interest income	1	1	1	5	9	5
Interest expense	86	74	59	137	126	107
Other income (expense)	100	(36)	31	96	(17)	(23)
Income tax expense (benefit)	82	82	130	101	68	43
Net income (loss)	364	391	486	475	22	(144)
Earnings per share, basic USD per share	7.35	7.77	9.57	9.27	0.20	(2.91)
Earnings per share, diluted USD per share	7.20	7.60	9.48	9.22	0.20	(2.91)
Weighted average shares, basic millions of shares	50	50	51	51	51	50
Weighted average shares, diluted millions of shares	51	51	51	51	52	50

Fiscal years (CRL's year ends in late December)

In millions of dollars	FY 2020Dec 26, 2020	FY 2021Dec 25, 2021	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Dec 27, 2025
Cash and cash equivalents	228	241	234	277	195	214
Short-term investments	1	1	—	—	—	—
Accounts receivable	618	643	752	780	721	709
Inventory	186	199	256	380	279	299
Prepaid and other current assets	73	97	108	83	106	129
Total current assets	1,201	1,274	1,439	1,609	1,403	1,447
Property and equipment, net	1,124	1,291	1,466	1,640	1,604	1,655
Right-of-use asset	178	293	392	394	412	361
Goodwill	1,809	2,712	2,850	3,095	2,847	2,764
Total assets	5,491	7,024	7,603	8,195	7,528	7,135
Accounts payable	122	198	206	169	140	149
Accrued liabilities	150	229	220	228	232	270
Current portion of long-term debt	47	0	1	3	0	0
Total current liabilities	840	1,033	1,092	1,055	994	1,120
Lease liability, non-current	156	253	390	419	484	434
Total liabilities	3,347	4,432	4,579	4,536	4,020	3,924
Retained earnings	625	981	1,433	1,887	1,812	1,389
Total stockholders' equity	2,115	2,535	2,976	3,597	3,462	3,165
Total liabilities and equity	5,491	7,024	7,603	8,195	7,528	7,135
Common shares outstanding (cover page) millions of shares	50	50	51	51	51	49

Fiscal years (CRL's year ends in late December)

In millions of dollars	FY 2020Dec 26, 2020	FY 2021Dec 25, 2021	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Dec 27, 2025
Net income (loss)	364	391	486	475	22	(144)
Stock-based compensation	56	71	74	72	70	71
Depreciation and amortization	235	266	304	314	362	403
Net cash from operating activities	547	761	620	684	735	738
Net cash from investing activities	(602)	(1,438)	(608)	(563)	(245)	(209)
Share repurchases	24	41	39	24	119	361
Proceeds from long-term debt	2,231	6,951	2,952	776	1,082	1,228
Net cash from financing activities	47	673	(42)	(86)	(551)	(537)
Net change in cash	(7)	13	(5)	43	(79)	10

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Charles River Laboratories International	200	983	254*	47.9M	Q3 FY26 10-QSep 26, 2026
Medpace Holdings	705	716	217*	28.0M	Q3 FY26 10-QSep 30, 2026
Incyte	3,276	1,557	(675)*	203.8M	Q3 FY26 10-QSep 30, 2026
UL Solutions	1,016	823	215*	not reported	Q3 FY26 10-QSep 30, 2026
Iqvia Holdings	2,249	4,428	825*	164.8M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 8, 2026, 6:21 AM ET. The filing on SEC.gov is the record.